Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.67 |
| ▸ | CNR2 | P34972 | 9/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170732 | 0.92 | CNR1 (0.57) | CNR1CNR2KDM4EMEN1CYP1A2 | |
| SCHEMBL10170809 | 0.91 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL10170805 | 0.91 | CNR2 (0.75) | CNR1CNR2KDM4EMEN1CYP1A2 | |
| SCHEMBL10170935 | 0.89 | CNR1 (0.65) | CNR1CNR2KDM4EMEN1CYP1A2 | |
| SCHEMBL13191028 | 0.89 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL10171047 | 0.85 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL10171672 | 0.84 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL10170792 | 0.84 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL10171048 | 0.82 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL10170979 | 0.82 | CNR1 (0.68) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046280-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | UNIVERSITY OF CONNECTICUT | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046280-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | CNR1, CNR2, CBR3 | CNR1 1/4885CNR2 2/4885KDM4E 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.